stride study semaglutide Sex Differences in Effectiveness of in Patients With Peripheral Artery Disease: The Trial Making Strides: Global Research Finds

Retatrutide (research code LY-3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a novel triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), and glucagon receptor (GCG-R)

The glucagon-like peptide-1 analogue liraglutide reduces seizures susceptibility, cognition dysfunction and neuronal apoptosis in a mouse model of Dravet syndrome

It's the non-negotiable foundation for success

PlexusDx's Precision Peptide Genetic Test reveals predispositions in these pathways, supporting more informed conversations about treatment optimization with your provider

How do antihistamines reduce Asian glow

Extracellular fluid viscosity enhances cell migration and cancer dissemination